André van der Ven and Mihai Netea, theme Infectious diseases and global health, and colleagues, will receive 15 million Euro from pharmaceutical company ViiV Healthcare for research into new ways to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV.Collaboration will process anonymised patient data, genetic information and environmental factors in order to understand the biology associated with HIV better and identify targets for new medicines earlier.
ViiV Healthcare is announcing a five-year collaboration with researchers of the Radboudumc, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). The HFGP is a large-scale project that combines detailed patient data with cross-omics information, host immune responses and environmental factors to better understand how the body recognizes and defends itself from disease as well as the signs, symptoms and progression of disease.
Under the supervision of a Scientific Management Board (SMB) comprising representatives from Radboudumc and ViiV Healthcare, Radboudumc will expand the cohort of HIV-infected individuals that are part of the HFGP from 200 to 2000 people. Data from this cohort will be used to look at the predictors and pathways of diseases that are specific to people living with HIV and how they might differ from other disease areas and from healthy people who do not have HIV. Using that information, the goal is to identify early stage drug targets that ViiV Healthcare could use to develop new medicines or approaches to treat HIV infection.
The project, called 'HIV 2000+' will be the first comprehensive cohort study in HIV to use a field of biology called 'cross-omics,' which uses genomics, microbiome metagenomics and metabolomics technologies to better understand the underlying biology associated with HIV infection.
Jan van Lunzen, MD PhD, Head of Translational Medical Research at ViiV Healthcare and project coordinator said: “This project will enable us to establish one of the best characterized cohorts of people living with HIV in the world and will not only help to better define biomarkers and pathways of disease progression, but may also serve as a fantastic platform to find new drug targets.”
The collaboration will combine Radboudumc’s experience in infectious diseases, established networks and scientific techniques with ViiV Healthcare’s expertise and innovation in discovering and developing medicines for HIV.
Mihai Netea said: “This is a unique, first-time collaboration which will combine in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV. It is a unique chance to understand the HIV infection and its complications better, and to partner with ViiV Healthcare to translate that knowledge to the bed of the patient.”
Deal termsViiV Healthcare will fully fund the five-year collaboration that will analyze cross-omics data from 2,000 HIV-infected patients and compare this data to that from other disease-areas and to data from healthy volunteers. Scientists from both Radboudumc and ViiV Healthcare will collaborate closely on the work packages that will be formed as part of the collaboration.
A SMB, comprising members from both Radboudumc and ViiV Healthcare, will provide both scientific and financial oversight of the collaboration. An Independent Scientific Advisory Board will be formed to advise the SMB.
Related news items
Dutch Brain Foundation grant for EENnacoma20 February 2020
Lavrijsen and Van Erp: ‘This grant will facilitate practice-based research, professionalization and further academization of EENnacoma, and links between different health care and research institutions all for the benefit of people with prolonged disorders of consciousness and their families.'read more
RIHS Awards Ceremony five winners19 February 2020
On 18 February the RIHS 'Koek & Zopie' event took place. In front of an audience of more than 125 colleagues, RIHS awardees accepted their awards for the best PhD thesis, the research product with the highest impact on society, the best peer-reviewed publication and the Supervisor of the year 2019.read more
Preserved specific force in facioscapulohumeral muscular dystrophy19 February 2020
DCMN researcher Saskia Lassche et al., theme Disorders of Movement, recently showed in Neurology that remaining muscle fibers in Facioscapulohumeral muscular dystrophy (FSHD) patients have normal muscle strength, even in severely affected muscles.read more
Researchers investigate how stem cells affect the immune system18 February 2020
RIMLS researchers Irma Joosten and Renate van der Molen, participating in an European study into the treatment of brain damage in premature babies. Is it possible to limit or even partly repair the damage with stem cells? They focus primarily on the effect of those stem cells on the immune system.read more
Lowlands Science call for projects17 February 2020
Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.read more